PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Alprostadil - Erectile dysfunction

PAD Profile : Alprostadil - Erectile dysfunction Important

Keywords :
ED, impotence, urethral stick
Brand Names Include :
Vitaros, MUSE, Caverject, Viridal Duo
Important Information :
Treatments for ED on the NHS require an SLS endorsement.

Traffic Light Status

Status 1 of 3.

Status :
Green (see narrative)
Important
Formulations :
  • Cream
Important Information :
Only in patients who do not respond to PDE-5 inhibitors.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :
Type
Document
Review Date

Status 2 of 3.

Status :
Blue
Important
Formulations :
  • Intraurethral
Important Information :
Patient to be provided with training materials prior to request for primary care prescribing.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
Blue
Important
Formulations :
  • Intracavernosal injection
Important Information :
Initiation and assessment of efficacy prior to transfer to primary care.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
05 June 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Alprostadil intra-urethral applications may be initiated in primary care following specialist recommendation.

The patient must have been provided with, or directed to, training materials to support self-administration before prescribing is requested from the GP.

Alprostadil intracavernosal injections should be initiated in secondary care, patients trained to self-administer and treatment shown to be effective before discharge for GPs to prescribe.

Alprostadil cream (Vitaros) is restricted by SLS criteria as identified in the Health Service Circular (HSC) 1999/148 at a maximum frequency of dosing of four times per month.

Alprostadil cream (Vitaros®) is a treatment option in primary care for patients who do not respond to PDE-5 inhibitors. This can be initiated in primary care and is considered GREEN on the traffic light system

Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use. 

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More